+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy



Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy



Gynecologic Oncology. 46(3): 357-360



Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008690288

Download citation: RISBibTeXText

PMID: 1526515

DOI: 10.1016/0090-8258(92)90232-8


Related references

'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. International Journal of Gynecological Cancer 4(4): 272-278, 1994

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 72(1): 55-60, 2001

No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer. Gynecologic Oncology 141: 53-54, 2016

Cisplatin, adriamycin, and cyclophosphamide (PAC) combination chemotherapy in stage IIIIV epithelial ovarian cancer: 7-Year follow-up. Gynecologic Oncology 23(2): 259-260, 1986

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience. European Journal of Cancer 27(10): 1211-1215, 1991

No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients. Asian Pacific Journal of Cancer Prevention 15(10): 4275-4279, 2014

Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. International Journal of Gynecological Cancer 17(6): 1231-1237, 2007

Response 2nd look status and survival in stage iii and stage iv epithelial ovarian cancer treated with cis di chloro di ammine platinum ii adriamycin and cytoxan. Gynecologic Oncology 10(3): 367-368, 1980

Seven year follow up of patients receiving cisplatin adriamycin and cyclophosphamide chemotherapy for stage iii and iv epithelial ovarian carcinoma. Proceedings American Society of Clinical Oncology Annual Meeting 5: 120, 1986

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. Journal of Oncology 2014: 312193, 2014

Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential. European Journal of Gynaecological Oncology 12(6): 451-455, 1991

Chemotherapy versus radiotherapy for stage iii iv ovarian cancer patients with minimal residual disease after cisplatin based chemotherapy. Cancer Investigation 9(3): 382-384, 1991

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade). International Journal of Gynecological Cancer 5(2): 134-142, 1995

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. Journal of Clinical Oncology 6(6): 983-989, 1988

The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. Clinical and Translational Oncology 21(10): 1357-1363, 2019